NHS Improvement steps up to the claim that a better transition care of young cancer patients is needed by creating a new publication to focus on the issue.
NHS Improvement has launched Models of care to achieve better outcomes for children and young people living with and beyond cancer. The new publication details the learning and evidence gathered from their work around improving the transition care of children and young people who are living with or have survived cancer.
It is widely recognised that there is a need for transition care which is co-ordinated and cohesive. NHS Improvement in conjunction with stakeholders within the Children and Young People National Cancer Survivorship Initiative have worked with various test sites to examine current care and find specific ways in which it can be improved.
As a result of the initiative, 13 key recommendations have been identified, which will contribute to after-care that is cost-effective and delivered by the appropriate health professionals to ensure the best use of skill mix and resources.
Alongside the recommendations, national pathways have been developed which identify how follow up for children and young people can be delivered in line with current pressures and aspirations. The pathways build upon the learning from varied national testing work and will help inform commissioners of the requirements of children and young people living with and surviving cancer.
In addition, four models of care have been produced which provide a core set of options for commissioners to consider, to meet the appropriate needs of individual patients.
The publication was launched at the 5th National Children & Young People (CYP) Survivorship Workshop. The workshop provided an opportunity to hear patient perspective and present the evidence so far, including pathways, models of care and risk stratified levels. Speakers included Alison Leiper, associate specialist in paediatric oncology and late effects of treatment for malignant disease, Great Ormond Street Hospital for Children, and Helen Hatcher, consultant in medical and TYA oncology, University of Cambridge.